Alzheimer’s & Dementia
(2018) 1-11

Featured Article

Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer’s disease

Min Shi1, Lu Tang1, Jon B. Toledo, Carmen Gingham, Hua Wang1, Patrick Aro1, Poul H. Jensen1, Daniel Weintraub1, Alice S. Chen-Plotkin1, David J. Irwin1, Murray Grossman1, Leo McCluskey1, Lauren B. Elman1, David A. Wolk1, Edward B. Lee1, Leslie M. Shaw1, John Q. Trojanowski1, Jing Zhang1,*

1Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA
2Department of Neurology, Peking University Third Hospital, Beijing, China
3Departments of Pathology and Laboratory Medicine, Psychiatry, Neurology and Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
4Department of Pathology, Peking University Health Science Centre and Third Hospital, Beijing, China
5DANDRITE-Danish Research Institute of Translational Neuroscience & Department of Biomedicine, University of Aarhus, Aarhus, Denmark

Abstract

Introduction: The ability of Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid β peptide 1–42, total tau, and phosphorylated tau) to discriminate AD from related disorders is limited. Biomarkers for other concomitant pathologies (e.g., CSF α-synuclein [α-syn] for Lewy body pathology) may be needed to further improve the differential diagnosis.

Methods: CSF total α-syn, phosphorylated α-syn at Ser129, and AD CSF biomarkers were evaluated with Luminex immunoassays in 367 participants, followed by validation in 74 different neuropathologically confirmed cases.

Results: CSF total α-syn, when combined with amyloid β peptide 1–42 and either total tau or phosphorylated tau, improved the differential diagnosis of AD versus frontotemporal dementia, Lewy body disorders, or other neurological disorders. The diagnostic accuracy of the combined models attained clinical relevance (area under curve ~0.9) and was largely validated in neuropathologically confirmed cases.

Discussion: Combining CSF biomarkers representing AD and Lewy body pathologies may have clinical value in the differential diagnosis of AD.

© 2018 the Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.

Keywords: Alzheimer’s disease; Differential diagnosis; Biomarkers; Cerebrospinal fluid; α-synuclein

1. Introduction

Investigations using biochemical measures in cerebrospinal fluid (CSF) as Alzheimer’s disease (AD) biomarkers have shown great promise, and such CSF biomarkers have been incorporated into recent guidelines for informed diagnosis of AD [1]. Specifically, CSF markers of core AD pathology (i.e., amyloid β peptide 1–42 [Aβ42] reflecting Aβ in plaque burden, and total tau [t-tau] and phosphorylated tau [p-tau] for assessing neurofibrillary tangles in the brain) provide both high sensitivity and specificity (80% or above) in differentiating patients with AD or mild cognitive impairment (MCI; prodromal AD) from healthy controls (HCs) [2–4]. However, the diagnostic accuracy of these CSF biomarkers in the differential diagnosis of AD and other dementias is limited (40%–80% sensitivity and specificity)
due to a substantial overlap in the CSF levels of these proteins [4–9]. A recent large-scale international multicenter study [5] suggested that the limited utility of these core CSF biomarkers to discriminate AD from a variety of related disorders could be due to the overlap in the underlying primary pathologies, and introduction of additional CSF biomarkers reflecting other types of pathologies could be of value to optimize the differential diagnosis [4,5], though reliance on clinical diagnoses might underestimate the accuracy of CSF biomarkers [10].

Among the concomitant non-AD type pathologies in AD, α-synuclein (α-syn)-positive Lewy bodies (LBs), the pathological hallmark of another family of neurodegenerative diseases including Parkinson disease (PD) and dementia with Lewy bodies (DLB), can be observed in up to 50% of familial and sporadic AD patients at autopsy [11–13]. We have reported that CSF total α-syn and phosphorylated α-syn at Ser129 (pS129) help differentiate PD from AD and other related neurodegenerative diseases [14–16]. More recently, we also found that CSF total α-syn improved the diagnostic and prognostic performance of CSF Aβ42 and tau in AD [17,18]. In this study, to test whether inclusion of CSF α-syn that represents brain LB pathology could improve the differential diagnosis of AD and other dementias, we further evaluated the utility of CSF total α-syn and pS129 in the differential diagnosis in a relatively large clinical cohort, followed by validating our findings in a separate cohort of neuropathologically confirmed cases.

2. Methods

2.1. Subjects

Two cohorts of research participants were recruited at the AD Core Center, the Penn Memory Center, the Frontotemporal Degeneration (FTD) Center, the Amyotrophic Lateral Sclerosis (ALS) Center, the PD and Movement Disorder Clinic, and the Penn Udall Center for Parkinson’s Research at the University of Pennsylvania [19]. The clinical or discovery cohort (n = 540) of clinically diagnosed participants included 165 AD, 105 MCI, 70 FTD (including 60 behavioral variant FTD and 10 corticobasal syndrome), 79 LB disorders (LBD; including 16 DBL and 63 PD or PD with dementia [PDD]), 41 ALS, 11 progressive supranuclear palsy (PSP), and 69 HC (see Table 1 and Supplementary Table 1). The validation cohort contained 102 neuropathologically confirmed cases, including 40 AD, 23 frontotemporal lobar degeneration with and without AD (FTLD; 17 FTLD, and 6 FTLD-AD), 30 PD or Lewy body–related pathology with and without AD (LRP) (three PD, four PD-AD, 21 LRP-AD, and two LRP with transactive response DNA-binding protein 43 pathology [LRP-TDP]), and six ALS (see below, Table 2, and Supplementary Table 2 for more details; note that three HC cases with an unremarkable burden of any significant brain pathology were not included in the analyses in the present study due to the small case number). The clinical diagnoses were made by applying clinical diagnostic criteria for AD [1], behavioral variant FTD [20], corticobasal syndrome [21], primary progressive aphasia [22], DLB [23], PD or PDD [24,25], ALS [26], PSP [27], and HC as previously reported [19,28,29]. For the purposes of this study, patients diagnosed as corticobasal syndrome, behavioral variant FTD, FTD-motor neuron disease, progressive nonfluent aphasia, and semantic dementia were classified as FTD, whereas subjects with AD and logopenic progressive aphasia were classified as AD. As per current conventions, the term FTD was used for the clinical diagnosis, and the term FTLD for the neuropathologically confirmed diagnoses. Informed consent to be included in research studies and to perform the autopsy was obtained in all cases from the patients or legal representatives in accordance with the Pennsylvania state law. The study and all protocols were approved by the Institutional Review Boards of the University of Pennsylvania and the University of Washington.

2.2. CSF collection and CSF measurements

All CSF samples were obtained by lumbar puncture as described previously, and samples were immediately stored at −80°C until analysis [30]. CSF total α-syn and pS129 levels were measured at the University of Washington by using Luminex immunoassays as previously described [14,16]. CSF data for Aβ42, t-tau, and p-tau were obtained at the University of Pennsylvania by using the INNO-BIA AlzBio375 Luminex assay reagents (Innogenetics, Ghent, Belgium) [30–32]. CSF hemoglobin levels were measured as an index of red blood cell contamination, using a human hemoglobin ELISA quantitation kit (Bethyl Laboratories Inc, Montgomery, TX, USA) as previously described [14].

2.3. Tissue collection and neuropathological assessment

Tissue collection procedures have been previously described [19]. Briefly, a neuropathological diagnosis of AD was assigned if the probability was intermediate or high [33]. The diagnoses of FTLD-TAU, FTLD-TDP, and DBL were based on established criteria [23,34]. FTLD-TAU cases included cases with a diagnosis of argyrophilic grain disease, PSP, tangle predominant senile dementia, and corticobasal degeneration. See Supplementary Methods for more details.

2.4. Statistical analysis

All analyses were performed in SPSS 18.0 (IBM, Chicago, IL, USA) or Prism 6.0 (GraphPad Software, La Jolla, CA, USA). Immunoassay data (CSF total α-syn, pS129, Aβ42, t-tau, and p-tau) were Log10 transformed to generate a more normally distributed data set, and the transformed data were used in all analyses. Correlations between biomarkers are reported as Pearson correlation coefficients. One way analysis of variance followed by Tukey post hoc
test was used to compare group means. Receiver operating characteristic (ROC) curves for analytes, controlling for age and sex of participants, were generated to evaluate their sensitivities and specificities in distinguishing AD from HC or diseased comparison participants. Area under curve (AUC) was determined as a measure of the overall performance of a diagnostic test (the closer the AUC is to 1, the better the overall diagnostic performance), which is also independent of disease prevalence because it is based on sensitivity and specificity [35]. The “optimum” cutoff value for an ROC curve was defined as the value associated with the maximal sum of sensitivity and specificity (i.e., maximizing the Youden index). Stepwise logistic regression was used to determine the best prediction models that included multiple CSF biomarkers as well as age and sex of participants. Values with $P < .05$ were regarded as significant.

### 3. Results

#### 3.1. Correlation among CSF analytes in the whole cohort

A total of 642 cases were included in the present study. As previously described [14,15], CSF $\alpha$-syn showed a strong association with CSF hemoglobin levels (an index of blood contamination in CSF; $r = 0.523$, $P < 3.8 \times 10^{-46}$) (Fig. 1A). CSF pS129 showed a significant, although weaker, inverse association with CSF hemoglobin levels ($r = -0.182, P < 3.6 \times 10^{-10}$ (Fig. 1B). When using a cutoff of hemoglobin $>500$ ng/mL in this cohort to exclude blood-contaminated samples, 31.3% of the CSF samples were excluded from all further analyses (n = 201) and then both CSF $\alpha$-syn ($P = .869$) and pS129 ($P = .291$) showed no significant associations with CSF hemoglobin.

After excluding CSF samples with high hemoglobin levels ($>500$ ng/mL), CSF $\alpha$-syn showed no association with CSF Aβ42 ($r = -0.025, P = .597$) (Fig. 1C) but a strong positive correlation with t-tau ($r = 0.725, P < 1.5 \times 10^{-71}$) (Fig. 1D) as well as a moderate positive correlation with p-tau ($r = 0.430, P < 3.0 \times 10^{-21}$) (Fig. 1E). In contrast, CSF pS129 showed no association with any of the three classic AD CSF biomarkers (all $P > .07$). CSF $\alpha$-syn and pS129 were not significantly correlated with each other ($r = -0.069, P = .15$) in this cohort (Fig. 1F).

#### 3.2. Evaluation of diagnostic and differential diagnostic values of CSF $\alpha$-syn and pS129 in the clinical cohort

A cohort of 540 cases without neuropathological confirmation was used as the discovery cohort in this study (see Supplementary Table 1 for the whole cohort). As described in the Section 2, certain disease groups were combined together based on their similar underlying pathology (e.g., DLB and PD/PDD) to increase the sample size in analyses. In this cohort (n = 367 subjects after excluding samples with high hemoglobin levels), CSF $\alpha$-syn levels were numerically higher in AD than those in HC; LBD (DLB/ PD/PDD; $P = .15$), or PSP ($P = .068$) (see Table 1 and
Fig. 2A). However, CSF α-syn was significantly higher in AD than in FTD (P = .004) or ALS (P = .014). CSF α-syn was also significantly higher in MCI than that in FTD (P = .001), LBD (P = .034), ALS (P = .003), or PSP (P = .023). CSF pS129 showed no differences between AD and MCI or HC, consistent with previous reports [16,36], or any other diagnostic groups (Fig. 2B). Using the CSF pS129/α-syn ratio did not enhance the performance of CSF total α-syn for AD diagnosis and differential diagnosis (Fig. 2C).

To further evaluate the diagnostic and differential diagnostic values of CSF biomarkers and their combinations, ROC analysis was performed to determine the sensitivities and specificities between AD and HC or patients with other neurodegenerative diseases (see Table 3 and Fig. 3). For the comparison between AD and HC, although CSF α-syn alone only provided a poor differentiation and as expected, CSF Aβ42 (AUC = 0.890, 95% CI 0.832–0.948; sensitivity = 86.8% [95% CI 79.2%–92.4%], specificity = 83.3% [95% CI 69.8%–92.5%]) or t-tau (AUC = 0.848, 95% CI 0.783–0.912; sensitivity = 77.2% [68.4%–84.5%], specificity = 83.3% [69.8%–92.5%]) could discriminate the two groups well, the best model was the combination of CSF Aβ42, t-tau, and α-syn, when controlling for age and sex of participants (AUC = 0.931, 95% CI 0.890–0.973; sensitivity = 92.1% [85.5%–96.3%], specificity = 85.4% [72.2%–93.9%]; Fig. 3A).

For the comparison between AD and FTD groups, CSF α-syn alone (controlling for age and sex of participants) could provide a weak differentiation (AUC = 0.760, 95% CI 0.687–0.832; sensitivity = 51.8% [42.2%–61.2%], specificity = 89.3% [78.1%–96.0%]), similar to those of CSF Aβ42, t-tau, or p-tau alone (Table 3); a combination of CSF α-syn, Aβ42, and p-tau differentiated AD from FTD well (AUC = 0.893, 95% CI 0.845–0.941; sensitivity = 80.7% [72.3%–87.5%], specificity = 85.7% [73.8–93.6%]; Fig. 3B) and was significantly more informative compared with the best individual CSF biomarker (Aβ42; Z = 2.3744, P = .0176, DeLong’s test [37]). Similarly, CSF α-syn alone could also provide a moderate differentiation for AD versus LBD (DLB/PD/PDD) (AUC = 0.751, 95% CI 0.664–0.838; sensitivity = 78.1% [69.4%–85.3%], specificity = 64.3% [48.0%–78.4%]), AD versus ALS (AUC = 0.858, 95% CI 0.788–0.928; sensitivity = 87.7% [80.3%–93.1%], specificity = 68.6% [50.7%–83.1%]), and AD versus PSP (AUC = 0.740, 95% CI 0.539–0.940; sensitivity = 70.2% [60.9%–78.4%], specificity = 77.8% [40.0%–97.2%]), and adding CSF α-syn to Aβ42, t-tau (or p-tau) enhanced the differential diagnosis (AD versus LBD, AUC = 0.900, 95% CI 0.844–0.956, sensitivity = 89.5% [82.3%–94.4%], specificity = 82.1% [62.5%–92.5%], Fig. 3C; AD versus ALS, AUC = 0.947, 95% CI 0.883–1.000, sensitivity = 96.5% [91.3%–99.0%], specificity = 88.6% [73.3%–96.8%], Fig. 3D; and AD versus PSP, AUC = 0.915, 95% CI 0.860–0.970, sensitivity = 80.7% [72.3%–87.5%], specificity = 100.0% [66.4%–100%], Table 3).

3.3. Validation of differential diagnostic values of CSF biomarkers in the autopsy cohort

To further validate the differential diagnostic values, we measured the CSF biomarkers in a cohort of neuropathologically confirmed cases (n = 102 in total; 74 after excluding CSF samples with >500 ng/mL hemoglobin levels; see Table 2 and Supplementary Table 2). Due to the limited...
number of cases, the subjects were categorized into the following pathological groups: AD, FTLD (including FTLD and FTLD-AD), LRP (including PD, PD-AD, LRP-AD, and LRP-TDP), and ALS. As shown in Fig. 4, consistent with the results from the clinical cohort, CSF α-syn was substantially higher in AD than that in FTLD, LRP, and ALS, whereas CSF pS129 did not show significant differences among diagnostic groups.

Further ROC analysis demonstrated that CSF α-syn could differentiate AD from FTLD (AUC = 0.782, \(P = 0.002\), sensitivity = 58.6\% [95\% CI 38.9\%–76.5\%], specificity = 93.8\% [69.8\%–99.8\%]; Fig. 4C), LRP (AUC = 0.678, \(P = 0.033\), sensitivity = 79.3\% [95\% CI 60.3\%–92.0\%], specificity = 57.1\% [34.0\%–78.2\%]; Fig. 4D), and ALS (AUC = 0.966, \(P = 0.001\), sensitivity = 86.2\% [95\% CI 68.3\%–96.1\%], specificity = 100.0\% [47.8\%–100.0\%]) well, when controlling for age and sex of participants. In addition, the combinations of CSF α-syn, Aβ_{42}, and t-tau (or p-tau) further improved the differential diagnosis: AD versus FTLD, AUC = 0.935, \(P = 1.67 \times 10^{-6}\), sensitivity = 93.1\% (95\% CI 77.2\%–99.2\%), specificity = 87.5\% (61.6\%–98.4\%) for a model of CSF α-syn, Aβ_{42}, and p-tau (Fig. 4E); AD versus LRP, AUC = 0.767, \(P = 0.001\), sensitivity = 55.2\% (95\% CI 35.7\%–73.6\%), specificity = 95.2\% (76.2\%–99.9\%) for a model of CSF α-syn, Aβ_{42}, and t-tau (Fig. 4F); and AD versus ALS, AUC = 1.000, \(P = 4.23 \times 10^{-4}\), sensitivity = 100.0\% (95\% CI 88.1\%–100.0\%).
specificity = 100.0% (47.8%–100.0%) for a model of CSF α-syn, Aβ42, and p-tau. It should be noted that some small sample sizes (e.g., n = 5 for ALS) led to wide 95% CIs.

4. Discussion

For the clinically relevant diagnosis and differential diagnosis of AD, it is essential to have a set of biomarkers that discriminate AD from other clinically relevant dementias or neurodegenerative diseases. Previous studies revealed substantial overlaps in CSF biomarker profiles (Aβ42 and t-tau or p-tau) between AD and related disorders, and this significantly limits the utility of these core CSF biomarkers in differential diagnosis [5,6]. In the present study, we interrogated CSF samples obtained from a relatively large, longitudinally followed clinical cohort, and we report that higher CSF total α-syn might be relatively unique to AD and that by combining data on CSF measures of α-syn, Aβ42, and t-tau or p-tau, we might be able to provide better diagnostic and differential diagnostic biomarker values for AD. These findings were largely confirmed in a separate cohort of participants who were longitudinally followed to autopsy for neuropathological confirmation of their diagnoses.

Although it was less apparent in the cohort included in this study, there is overlap of CSF Aβ42 and tau values between AD and related disorders as reported in previous studies [5–9]. As discussed previously [5,6], these observations were not that surprising because mixed pathology is a common finding at autopsy [38–41], which may reflect converging pathophysiological mechanisms and pathways at late clinical stages [5]. For example, neuropathological and neuroimaging studies have revealed Aβ and tau pathology in LBD patients [42–44], and the regional brain Aβ accumulation appears to correlate with domain-specific cognitive performance in PD patients [45]. These results suggest that CSF Aβ42 and tau may detect the increased levels of Aβ and tau pathology in non-AD diseases, limiting the differential diagnostic value of such biomarkers [5], particularly when used alone. Earlier studies [46,47] reported that CSF p-tau might improve the differential dementia diagnosis (AUC 0.6–0.8), but other large-scale studies [4,5], including the present study, found that CSF p-tau and t-tau performed largely equally.

In the present study, CSF α-syn levels tended to be higher in AD or MCI than those in related disorders in both cohorts, though the statistical significance was not achieved for AD versus HC and AD versus LBD (DLB/PD/PDD). This is in agreement with several previous large-scale studies, showing significantly higher levels of α-syn in CSF from patients with AD compared with HC [17,18,36] or patients with DLB/PDD [48]. The increase is perhaps due to the release of α-syn from damaged neurons during neurodegeneration, similar to what has been hypothesized for the increased levels of CSF tau in AD.
However, this cannot be the entire explanation because CSF α-syn and tau do not appear to be increased in most other neurodegenerative diseases that are also associated with α-syn or tau pathology and extensive neuron loss in the brain. We have reported that CSF α-syn and tau could be transported from the central nervous system into peripheral blood, and this potential clearance of central nervous system α-syn and tau via exosomes appeared to be increased in PD compared with HC [49,50] but not in AD for tau [50] (α-syn clearance in AD has not been tested yet). Whether this is also true for central nervous system α-syn clearance and whether it could be a major contributor to the increase of CSF α-syn and tau in AD needs further investigation.

Most importantly, we found that the diagnostic accuracy of the combinations of these CSF biomarkers including measures of α-syn, Aβ, and tau was high enough (AUC, 0.8–0.9) to be useful in clinical settings for differentiating patients with AD from those with other related disorders. The diagnostic accuracy of these CSF proteins for differentiating AD from FTD is at least in the same order of magnitude as those obtained with advanced neuroimaging technologies [51,52] and at a lower cost. Our findings on AD versus LBD are also in line with a previous study [48] reporting that a panel of CSF biomarkers including α-syn, tau, and Aβ42 could differentiate AD from DLB and PDD with high sensitivity and specificity. It should be emphasized that these results were acquired from a retrospective study under a research setting and the biomarker accuracy and usefulness of the panel need to be further confirmed in prospective diagnostic studies under clinical settings [4]. In addition, we used AUC as well as the Youden index—determined sensitivity and specificity in this study to assess the overall performance of candidate biomarkers for the differential diagnosis of AD, which usually has higher prevalence rate among related diseases. In some clinical settings (e.g., to screen for a certain disease of very low prevalence, a high specificity, and a low false positive rate is required), the performance may need to be re-evaluated by adjusting the cutoff range or considering only a portion of the ROC curve.

However, CSF pS129 levels did not distinguish AD from any of the other diagnostic groups in this study. Previous studies have demonstrated that pS129 is the predominant post-translationally modified form of α-syn in LBs [53,54] and have also associated CSF pS129 with PD [16,55]. However, the role of pS129 in AD remains unclear despite the frequent observation of LBs in AD brains [11–13]. In our previous study [16], we did not observe significant differences in CSF pS129 levels between AD and HC when a small cohort of AD subjects was examined. This was confirmed in a more recent independent study with a much larger AD cohort [36]. In the present study, CSF pS129 and total α-syn were

<table>
<thead>
<tr>
<th>Table 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic and differential diagnostic values of CSF biomarkers in AD in the clinical cohort</td>
</tr>
<tr>
<td>Differential diagnosis</td>
</tr>
<tr>
<td>AD versus HC</td>
</tr>
<tr>
<td>AUC</td>
</tr>
<tr>
<td>Sensitivity%</td>
</tr>
<tr>
<td>Specificity%</td>
</tr>
<tr>
<td>P value</td>
</tr>
<tr>
<td>AD versus FTD</td>
</tr>
<tr>
<td>AUC</td>
</tr>
<tr>
<td>Sensitivity%</td>
</tr>
<tr>
<td>Specificity%</td>
</tr>
<tr>
<td>P value</td>
</tr>
<tr>
<td>AD versus LBD</td>
</tr>
<tr>
<td>AUC</td>
</tr>
<tr>
<td>Sensitivity%</td>
</tr>
<tr>
<td>Specificity%</td>
</tr>
<tr>
<td>P value</td>
</tr>
<tr>
<td>AD versus ALS</td>
</tr>
<tr>
<td>AUC</td>
</tr>
<tr>
<td>Sensitivity%</td>
</tr>
<tr>
<td>Specificity%</td>
</tr>
<tr>
<td>P value</td>
</tr>
<tr>
<td>AD versus PSP</td>
</tr>
<tr>
<td>AUC</td>
</tr>
<tr>
<td>Sensitivity%</td>
</tr>
<tr>
<td>Specificity%</td>
</tr>
<tr>
<td>P value</td>
</tr>
</tbody>
</table>

Abbreviations: α-syn, α-synuclein; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; AUC, area under curve; CSF, cerebrospinal fluid; FTD, frontotemporal degeneration; HC, healthy controls; LBD, Lewy body disorders; pS129, phosphorylated α-syn at Ser129; PSP, progressive supranuclear palsy; p-tau, phosphorylated tau at Thr181; Sens, sensitivity; Spec, specificity; t-tau, total tau.

1. Logistic model contains CSF α-syn, Aβ42, t-tau or p-tau, age, and sex of participants.

**M. Shi et al. / Alzheimer’s & Dementia (2018) 1-11**
not significantly correlated with each other, indicating that different α-syn forms in CSF might behave differently, possibly due to different transportation or clearance mechanisms. Our results also suggest that the transportation or clearance mechanisms for pS129, if different from other general α-syn species, might be less likely affected under different disease settings.

All the ROC analyses in this study were performed by controlling for age and sex of participants. Several studies have explored whether demographic factors, including age, sex, and the apolipoprotein E (APOE) ε4 genotype, impact the diagnostic accuracy of CSF AD biomarkers (see review by Mattsson et al. [4]). Although there is no clear effect of sex on the diagnostic accuracy, age may impact the diagnostic performance of CSF AD biomarkers [4]. The genotype APOE ε4 is strongly associated with reduced CSF Aβ42 in controls but not with altered CSF t-tau or p-tau levels [4] as well as CSF α-syn levels [17]. However, because APOE ε4 is associated with increased amyloid pathology, rather than artificial reductions of CSF Aβ42, it is not recommended to adjust the CSF Aβ42 cutoff depending on the presence of APOE ε4 [4]. In the present study, adding APOE ε4 status to the models did not change the outcomes (data not shown).

One limitation of this study is that the cohort studied here did not include any subjects with vascular dementia and thus the performance of CSF α-syn, together with Aβ42 and t-tau or p-tau, on differentiating AD from vascular dementia remains unknown. Although this needs to be further investigated in future studies, we previously reported that CSF E-selectin, a biomarker of endothelial function or vascular injury, might be a promising CSF biomarker to pursue as a potential indicator that vascular...
pathology is contributing to dementia [56]. Thus, CSF E-selectin should be tested in larger cohorts for its ability to differentiate AD from vascular dementia. Another potential limitation is that certain disease groups with similar underlying pathology were combined together (e.g., DLB and PD were combined into overarching LBD or LRP) to increase the sample size in the analyses, and its potential confounding effects need to be further investigated in future larger-scale studies.

In summary, CSF total \(\alpha\)-syn, when combined with core AD biomarkers (i.e., \(\alpha\)B42, t-tau, and p-tau), improved the differential diagnosis of AD versus FTD, LBD (DLB/PD/PDD) and other neurodegenerative diseases. The diagnostic accuracy of the combined models described here was high enough to be of clinical value for differentiating AD patients from patients with other related disorders in our cohort. Moreover, the diagnostic performance of these CSF biomarkers was supported by studies of a second cohort of subjects who were longitudinally followed to autopsy for neuropathological confirmation of their diagnoses. Although further validation in independent cohorts is still needed, our results indicate that CSF measures of total \(\alpha\)-syn combined with measures of \(\alpha\)B42, t-tau, and p-tau might have clinical value in the differential diagnosis of AD.

Acknowledgments

The authors deeply appreciate the participants for their generous donation of samples. This study was supported by grants from the National Institutes of Health (NIH) (U01 NS082137, U01 NS091272, and R56 AG057417 to J.Z., and P30 AG010124, P50 NS053488, and P01 AG017586-8499 to J.Q.T.) and grants from China (Z161100000216150, 2016YFC1306502 and XDA12040101 to J.Z.) The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
The sponsors of this study had no role in the study design, data collection, analysis and interpretation, or the writing of the report. The authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.


Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jalz.2018.02.015.

References


